A Phase I, Open-label Study to Assess the Absolute Bioavailability of Ceralasertib (AZD6738) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Ceralasertib in Patients With Non-small Cell Lung Cancer, Ovarian Cancer, or Endometrial Cancer
Latest Information Update: 08 Jan 2025
Price :
$35 *
At a glance
- Drugs Ceralasertib (Primary) ; Ceralasertib (Primary)
- Indications Endometrial cancer; Non-small cell lung cancer; Ovarian cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 08 Jan 2025 New trial record